These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 8832013)

  • 1. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Veno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantation.
    Batsis I; Yannaki E; Kaloyannidis P; Sakellari I; Smias C; Georgoulis I; Fassas A; Anagnostopoulos A
    Thromb Res; 2006; 118(5):611-8. PubMed ID: 16330084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.
    Simon M; Hahn T; Ford LA; Anderson B; Swinnich D; Baer MR; Bambach B; Bernstein SH; Bernstein ZP; Czuczman MS; Slack JL; Wetzler M; Herzig G; Schriber J; McCarthy PL
    Bone Marrow Transplant; 2001 Mar; 27(6):627-33. PubMed ID: 11319593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors.
    Hasegawa S; Horibe K; Kawabe T; Kato K; Kojima S; Matsuyama T; Hirabayashi N
    Bone Marrow Transplant; 1998 Dec; 22(12):1191-7. PubMed ID: 9894723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.
    Morris JD; Harris RE; Hashmi R; Sambrano JE; Gruppo RA; Becker AT; Morris CL
    Bone Marrow Transplant; 1997 Nov; 20(10):871-8. PubMed ID: 9404929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
    Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
    Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
    Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients.
    Essell JH; Thompson JM; Harman GS; Halvorson RD; Snyder MJ; Callander NS; Clement DJ
    Bone Marrow Transplant; 1992 Oct; 10(4):367-72. PubMed ID: 1422493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation.
    Salat C; Holler E; Wolf C; Kolb HJ; Reinhardt B; Pihusch R; Krämling HJ; Heinemann V; Haller M; Hiller E
    Bone Marrow Transplant; 1997 Mar; 19(5):487-90. PubMed ID: 9052916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study.
    Lee JH; Lee KH; Kim S; Lee JS; Kim WK; Park CJ; Chi HS; Kim SH
    Bone Marrow Transplant; 1998 Nov; 22(9):883-8. PubMed ID: 9827816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial.
    Attal M; Huguet F; Rubie H; Huynh A; Charlet JP; Payen JL; Voigt JJ; Brousset P; Selves J; Muller C
    Blood; 1992 Jun; 79(11):2834-40. PubMed ID: 1586733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
    Park SH; Lee MH; Lee H; Kim HS; Kim K; Kim WS; Jung CW; Im YH; Yoon SS; Kang WK; Park K; Park CH; Kim SW
    Bone Marrow Transplant; 2002 Jan; 29(2):137-43. PubMed ID: 11850708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of PGE1 to prevent veno-occlusive disease of the liver after bone marrow transplantation.
    Gluckman E; Jolivet I; Scrobohaci ML; Devergie A; Traineau R; Bourdeau-Espérou H; Lehn P; Faure P; Drouet L
    Nouv Rev Fr Hematol (1978); 1990; 32(1):1-3. PubMed ID: 2349075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma.
    Horn B; Reiss U; Matthay K; McMillan A; Cowan M
    Bone Marrow Transplant; 2002 Mar; 29(5):409-15. PubMed ID: 11919731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A trial use of prostaglandin E1 for prevention of hepatic veno-occlusive disease after allogeneic bone marrow transplantation].
    Morio S; Oh H; Kogure K; Ishii H; Ishii A; Nakaseko C; Ikegami T; Kawano E; Matsuura Y; Nishimura M
    Rinsho Ketsueki; 1994 Sep; 35(9):846-52. PubMed ID: 7967053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
    Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
    Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
    Ozkaynak MF; Weinberg K; Kohn D; Sender L; Parkman R; Lenarsky C
    Bone Marrow Transplant; 1991 Jun; 7(6):467-74. PubMed ID: 1908340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
    Remberger M; Ringdén O
    Transplantation; 1995 Dec; 60(11):1293-9. PubMed ID: 8525524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.